These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23758591)

  • 21. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT; Lee TW; Lo JM
    Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Facile preparation of cationic gold nanoparticle-bioconjugates for cell penetration and nuclear targeting.
    Ojea-Jiménez I; García-Fernández L; Lorenzo J; Puntes VF
    ACS Nano; 2012 Sep; 6(9):7692-702. PubMed ID: 22870984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Smart nanoprobes for ultrasensitive detection of breast cancer via magnetic resonance imaging.
    Lee J; Yang J; Seo SB; Ko HJ; Suh JS; Huh YM; Haam S
    Nanotechnology; 2008 Dec; 19(48):485101. PubMed ID: 21836291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells.
    Miyano T; Wijagkanalan W; Kawakami S; Yamashita F; Hashida M
    Mol Pharm; 2010 Aug; 7(4):1318-27. PubMed ID: 20527783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SERS imaging of HER2-overexpressed MCF7 cells using antibody-conjugated gold nanorods.
    Park H; Lee S; Chen L; Lee EK; Shin SY; Lee YH; Son SW; Oh CH; Song JM; Kang SH; Choo J
    Phys Chem Chem Phys; 2009 Sep; 11(34):7444-9. PubMed ID: 19690717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.
    Cruz LJ; Tacken PJ; Fokkink R; Figdor CG
    Biomaterials; 2011 Oct; 32(28):6791-803. PubMed ID: 21724247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
    Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
    Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-functionalized porous silicon nanoparticles for vectorization of hydrophobic drugs.
    Secret E; Smith K; Dubljevic V; Moore E; Macardle P; Delalat B; Rogers ML; Johns TG; Durand JO; Cunin F; Voelcker NH
    Adv Healthc Mater; 2013 May; 2(5):718-27. PubMed ID: 23203914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
    Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
    Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding and Internalization of Iron Oxide Nanoparticles Targeted to Nuclear Oncoprotein.
    Knight LC; Romano JE; Krynska B; Faro S; Mohamed FB; Gordon J
    J Mol Biomark Diagn; 2010; 1(1):. PubMed ID: 23487404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-Specific Delivery Using an Engineered Protein Nanocage.
    Levasseur MD; Mantri S; Hayashi T; Reichenbach M; Hehn S; Waeckerle-Men Y; Johansen P; Hilvert D
    ACS Chem Biol; 2021 May; 16(5):838-843. PubMed ID: 33881303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ligand Separation on Nanoconstructs Affects Targeting Selectivity to Protein Dimers on Cell Membranes.
    Wu YL; Lee K; Diloknawarit B; Odom TW
    Nano Lett; 2024 Jan; 24(1):519-524. PubMed ID: 38126338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analytical Techniques for Characterizing Tumor-Targeted Antibody-Functionalized Nanoparticles.
    Marques AC; Costa PC; Velho S; Amaral MH
    Life (Basel); 2024 Apr; 14(4):. PubMed ID: 38672759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials.
    Xu M; Han X; Xiong H; Gao Y; Xu B; Zhu G; Li J
    Molecules; 2023 Jun; 28(13):. PubMed ID: 37446806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2-Specific Peptide (LTVSPWY) and Antibody (Herceptin) Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study.
    Bayram NN; Ulu GT; Abdulhadi NA; Gürdap S; İşoğlu İA; Baran Y; İşoğlu SD
    Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymersome-based protein drug delivery - quo vadis?
    Gouveia MG; Wesseler JP; Ramaekers J; Weder C; Scholten PBV; Bruns N
    Chem Soc Rev; 2023 Jan; 52(2):728-778. PubMed ID: 36537575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells.
    Avvakumova S; Pandolfi L; Soprano E; Moretto L; Bellini M; Galbiati E; Rizzuto MA; Colombo M; Allevi R; Corsi F; Sánchez Iglesias A; Prosperi D
    Nanoscale Adv; 2019 Sep; 1(9):3626-3638. PubMed ID: 36133537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.